MajorAntiepileptics. Carboxamide derivatives×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Carbamazepine is one of the P-gp inducers that may lower edoxaban plasma levels (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Carbamazepine may reduce plasma levels of direct oral anticoagulants, edoxaban included, which carries a risk of thrombosis (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The resulting anticoagulant levels may be too low for the intended effect (carbamazepine label, US Food and Drug Administration, FDA). Neither the labels nor the European Heart Rhythm Association table says how much edoxaban levels fall (EHRA 2021).
Symptoms
The main risk is thrombosis because edoxaban works less well (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking.
Management
In general, avoid combining carbamazepine with edoxaban, as with rivaroxaban, apixaban and dabigatran (carbamazepine label, US Food and Drug Administration, FDA). If the combination cannot be avoided, monitor closely for signs and symptoms of thrombosis (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use caution when edoxaban is combined with P-glycoprotein (P-gp) inducers, carbamazepine included (edoxaban SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The Spanish carbamazepine SmPC lists oral anticoagulants, edoxaban included, among the drugs whose doses are adjusted to clinical need (AEMPS). The dosing section of the edoxaban SmPC, however, lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of carbamazepine, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). With carbamazepine, the doses of warfarin and acenocoumarol are also adjusted to clinical need (carbamazepine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Carbamazepina, Tegretol 200 mg (nº registro 39955), sección 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2